bluebird bio, Inc. (BLUE)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 1.0500 |
| Open | 1.0500 |
| Bid | 1.0300 x 800 |
| Ask | 1.0500 x 4400 |
| Day's range | 1.0200 - 1.0600 |
| 52-week range | 0.8500 - 5.5300 |
| Volume | |
| Avg. volume | 8,137,344 |
| Market cap | 198.524M |
| Beta (5Y monthly) | 0.87 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6300 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.16 |
- GuruFocus.com
bluebird bio Inc (BLUE) Q1 2024 Earnings: Surpasses Revenue Expectations with Strategic Focus ...
Detailed Analysis of Financial Performance and Future Outlook
Zacksbluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well
bluebird (BLUE) beats sales estimates in the first quarter on increased Zynteglo product revenues. The company is on track with the ongoing launch of its gene therapies.
Business Wirebluebird bio Reports First Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
SOMERVILLE, Mass., May 09, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported first quarter results and business highlights for the quarter ended March 31, 2024, including recent commercial and operational progress.
© 2024 Yahoo. All rights reserved.